Centrum gastroenterologie a hepatologie s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The centre investigates inflammatory bowel disorders, concentrating on Crohn's disease and ulcerative colitis, with the goal of testing a novel biologic agent to achieve both induction and maintenance of clinical remission.
- Induction of clinical remission in adults
- Maintenance therapy for sustained response
- Evaluation in both adult and adolescent participants
These studies are designed to improve outcomes for patients with moderately to severely active disease and to expand therapeutic options for chronic gastrointestinal inflammation.
Immune System Diseases
Research at Centrum gastroenterologie a hepatologie s.r.o. also targets the immune pathways that drive the gut inflammation, using the immune‑modulating compound icotrokinra in controlled clinical trials.
- Immune pathway inhibition strategies
- Placebo‑controlled efficacy assessment
- Comprehensive safety monitoring across age groups
Results are expected to deepen understanding of immune‑mediated disease mechanisms and may have implications for other immune system disorders beyond the gastrointestinal tract.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Janssen Cilag International2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum gastroenterologie a hepatologie s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ICOTROKINRA | 2 | Unknown | 2025-12-03 | 2025-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.